ArticleThe New England journal of medicine2015
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Article in The New England journal of medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03982680 (Clinical Study of Toripalimab Monoclonal Antibody Combined With Gemcitabine/5--fluoropyrimidine in the Treatment of Advanced Cholangiocarcinoma), which is not on this map. Cited by 152 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Study of Toripalimab Monoclonal Antibody Combined With Gemcitabine/5--fluoropyrimidine in the Treatment of Advanced Cholangiocarcinoma
Who cites it
152 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy or cetuximab in the treatment of platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a meta-analysis.Frontiers in pharmacology · 2026Pooled it
- The Efficacy and Safety of Durvalumab and Tremelimumab with Concomitant Treatment for MSS/pMMR Metastatic Colorectal Cancer: A Single Arm Meta-Analysis.Journal of gastrointestinal cancer · 2025Pooled it
- Efficacy and safety of first-line targeted and immunotherapy for metastatic colorectal cancer: a network meta-analysis.Frontiers in immunology · 2025Pooled it
- Toripalimab in patients with previously treated advanced upper tract urothelial carcinoma: a subgroup analysis of the phase II POLARIS-03 trial.The oncologist · 2026Trial
- Trial
- First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial.Signal transduction and targeted therapy · 2025Trial
- Combined PD-1, BRAF and MEK inhibition in BRAFNature medicine · 2023Trial
- An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.Oncoimmunology · 2026Article
- Mechanisms and advances of drug resistance in colorectal cancer: A systematic overview of multi-layered regulatory networks.Translational oncology · 2026Review
- Universal off-the-shelf TGF-Acta pharmaceutica Sinica. B · 2026Article
- Perioperative pancreatic ductal adenocarcinoma care in 2025: who needs neoadjuvant?-who needs radiation?Gland surgery · 2026Review
- Mitochondria-Targeting Iridium(III) Complexes Induce PANoptosis and Ferroptosis for Boosting Chemoimmunotherapy Against Immune-Desert Colorectal Cancer.Angewandte Chemie (International ed. in English) · 2026Article
- Current Strategies and Emerging Paradigms of Immunotherapy in Microsatellite Stable Colorectal Cancer: A Review Article.Clinical drug investigation · 2026Review
- CD44-Targeting Hydroxyapatite Nanoparticles (HAP) Induce Mitochondrial Dysfunction-Driven PANoptosis and Immunogenic Cell Death (ICD) via Ca Overload in Colorectal Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
- Comprehensive multi-omics analysis and experimental validation indicate that VPS35 is a promising biomarker for prognosis, immunotherapy, and chemotherapy in LIHC.RSC medicinal chemistry · 2026Article
- Immunogenic Cell Death-relevant Molecular Patterns, Prognostic Genes, and Implications for Immunotherapy in Ovarian Cancer.Current medicinal chemistry · 2026Article
- Dietary restriction-responsive genes define prognostic subtypes and predict metastasis in colorectal cancer.Translational cancer research · 2025Article
- Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000-2025).Journal of hematology & oncology · 2025Review
- NovumRNA: Accurate prediction of non-canonical tumor antigens from RNA sequencing data.iScience · 2025Article
92 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
26559583What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.